Literature DB >> 7265176

Plasma haemoglobin and complement activation in sickle cell disease.

K DeCeulaer, W A Wilson, A G Morgan, G R Serjeant.   

Abstract

The role of haemolysis in producing deficient complement function in homozygous sickle cell disease was studied by measuring indices of complement activation and of haemolysis in 30 asymptomatic patients. Plasma concentration of C3d (an index of increased C3 turnover) was elevated in 40% of patients, and modest decreases in serum concentration of C3 and functionally (haemolytically) active factor B were found. There was a positive correlation between C3d and plasma haemoglobin concentration (r = 0.56, p less than 0.005). Reticulocyte count and foetal haemoglobin concentration also contributed to variation in C3d, though to a lesser extent than plasma haemoglobin. Intravascular haemolysis in sickle cell disease may produce activation of complement and thus cause partial depletion of functional factor B and C3. This may reduce the immune function of the alternative pathway.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7265176

Source DB:  PubMed          Journal:  J Clin Lab Immunol        ISSN: 0141-2760


  5 in total

1.  Tuberculosis in children with sickle cell anaemia: a retrospective study in French tertiary care centres.

Authors:  Nina Droz; Agathe De Lauzanne; Laurent Holvoet; Florence Missud; Malika Benkerrou; Valentine Brousse; Marie-Hélène Odièvre; Albert Faye; Berengere Koehl
Journal:  Eur J Pediatr       Date:  2017-04-11       Impact factor: 3.183

Review 2.  Development of complement therapeutics for inhibition of immune-mediated red cell destruction.

Authors:  Karina Yazdanbakhsh
Journal:  Transfusion       Date:  2005-08       Impact factor: 3.157

3.  Pneumonia in young children with homozygous sickle cell disease: risk and clinical features.

Authors:  K De Ceulaer; K W McMullen; G H Maude; R Keatinge; G R Serjeant
Journal:  Eur J Pediatr       Date:  1985-09       Impact factor: 3.183

4.  Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients.

Authors:  R H Wang; G Phillips; M E Medof; C Mold
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

Review 5.  Life-Threatening Infectious Complications in Sickle Cell Disease: A Concise Narrative Review.

Authors:  Dominik Ochocinski; Mansi Dalal; L Vandy Black; Silvana Carr; Judy Lew; Kevin Sullivan; Niranjan Kissoon
Journal:  Front Pediatr       Date:  2020-02-20       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.